News | May 01, 2025
Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
The Subsidiary has received one inspectional observation in Form 483
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Alembic Pharmaceuticals commissions new facility at Pithampur
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
ekincare has raised a total funding of $22M since 2015 till date
The company has posted net profit of Rs. 406.7 crores for the Financial Year ended March 31, 2025
This approval authorizes the company to export Ibuprofen to the Chinese markets
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Subscribe To Our Newsletter & Stay Updated
